Medeor Therapeutics is a San Mateo, CA–based clinical-stage biotechnology company developing personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Its product candidates are unique compositions of hematopoietic, organ-donor–derived cells based on technologies discovered at Stanford and exclusively licensed by Medeor. The candidates are designed to produce mixed chimerism—coexistence of recipient and donor blood and immune cells—to achieve donor-specific immune tolerance, prevent transplant organ loss, and reduce or eliminate chronic immunosuppressive drug therapy. The company’s lead programs include MDR-101, MDR-102, MDR-103 and MDR-104, targeting different transplant settings (living donor HLA-matched, living donor HLA-mismatched, induction of delayed tolerance, and deceased donor patients, respectively). Medeor is led by co-founder, President and CEO Steven R. Deitcher, M.D. The company intends to use new financing to advance clinical development, including a Phase 3 trial of MDR-101 under a Special Protocol Agreement with the FDA and a Phase 2b trial of MDR-102, plus initiation of MDR-103 and MDR-104 development.

Total raised

$57M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2017